- Home
- BTMD vs ATYR Comparison
BTMD vs ATYR Comparison
Compare BTMD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | ATYR |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 73.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTMD | ATYR |
|---|---|---|
| Price | $1.39 | $0.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | $2.25 | ★ $4.20 |
| AVG Volume (30 Days) | 302.1K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $0.64 |
| 52 Week High | $4.75 | $7.29 |
Technical Indicators
Market Signals| Indicator | BTMD | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 49.57 |
| Support Level | $1.35 | $0.67 |
| Resistance Level | $1.69 | $0.85 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 27.71 | 63.54 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).